drugset / Trial / NCT00528437
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Phase 2
Completed
46 enrolled
NYU Langone Health
Children's Hospitals and Clinics of Minnesota · collabSchneider Children's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cis-retinoic acid has on children and adolescents with recurrent/refractory brain tumors Find out how the body uses 13-cis-retinoic acid by studying the your blood levels and proteins in the blood that break down the 13-cis-retinoic acid Determine how well 13-cis-retinoic acid penetrates into the spinal fluid.
Timeline
- Start
- 2005-10
- Primary completion
- 2017-06-30
- Completion
- 2017-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Isotretinoin | Other / unclassified | — | Oral |
| Subject | Temozolomide | Small molecule | — | Oral |
| Subject | Thiotepa | Other / unclassified | — | — |